News

Europe’s Pharma Industry Braces for Pain as Trump Tariff Threat Looms
Medicines and chemicals are huge exports for European Union countries. That makes the sector a weak spot as trade tensions ...
Pharma companies expected to absorb any tariff hit in short term
U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...
The Largest Healthcare Companies by Market Cap in April 2025
Eli Lilly ( NYSE:LLY) is the most valuable healthcare company, with UnitedHealth Group ( NYSE:UNH) and Johnson & Johnson ( ...
Sportschosun on MSN2d
Korea's bio-health industry is expected to rank 8th in the world in 2030...Korea Health Industry Promotion Agency publishes 2025 global bio-health industry market size
It is predicted that the size of Korea's bio-health industry market will rank 8th in the world by 2030. As of February this ...
Patient Inclusivity: The Missing Piece In Pharma’s Global Innovation Strategy
The pharmaceutical industry's next billion-dollar blockbuster won't come from a lab alone—it will come from listening to ...
WTOP News6d
7 Best Pharmaceutical Stocks to Buy for Income
AstraZeneca is one of the largest pure-play pharmaceutical companies in the world. Its leading commercial drugs include Tagrisso for lung cancer, Farxiga for type 2 diabetes and Soliris for ...
Opinion - Trump’s pharmaceutical tariffs will risk the lives of American patients
May. These duties won’t just be economically wasteful: They’ll pummel the U.S. health care system. Unlike the “reciprocal” ...
Lexaria provides GLP-1 update following industry developments
Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...
Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS?
UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...
European Pharma Companies Push for Higher Drug Prices in EU Amid U.S. Tariff Threats
"European price controls and austerity measures reduce the attractiveness of its markets," Novartis CEO Vas Narasimhan and ...
The Gazette12d
Analysis-Pharma companies expected to absorb any tariff hit in short term
Rates and timing remain uncertain, but the industry has been lobbying for phased-in tariffs. The hit could be big. Close to $213 billion in pharmaceutical products were imported to the U.S. last ...